congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Other/Multi
AACR 2024 | April 5-10, 2024
A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1
Poster
HER3-DXd
AACR 2024 | April 5-10, 2024
An evaluation of patritumab deruxtecan (HER3-DXd, U3-1402) against pediatric PDX models for hepatoblastoma and rhabdomyosarcoma – a report from the NCI PIVOT program
Poster
T-DXd
AACR 2024 | April 5-10, 2024
Concordance between the DESTINY-Breast04 clinical trial assay (4B5[CDx]) and other HER2 IHC assays for HER2-low breast cancer in real-world practice: First phase of a large-scale, multicenter global ring study
Poster
Dato-DXd
AACR 2024 | April 5-10, 2024
Dato-DXd mediates anti-tumor activity in preclinical TROP2-expressing intracranial tumor model
Oral
Other/Multi
AACR 2024 | April 5-10, 2024
DS-3939a, a novel TA-MUC1-targeting antibody-drug conjugate (ADC) with a DNA topoisomerase I inhibitor DXd, exhibits potent antitumor activity in preclinical models
Poster
T-DXd
AACR 2024 | April 5-10, 2024
Dual immune checkpoint blockade enhances the anti-tumor activity of trastuzumab deruxtecan in preclinical models
Poster
Dato-DXd
AACR 2024 | April 5-10, 2024
Evaluating the combination of datopotamab deruxtecan (Dato-DXd) with saruparib (AZD5305), a highly potent, PARP1-selective inhibitor, in preclinical models
Poster
Dato-DXd
AACR 2024 | April 5-10, 2024
Functional profiling in lung tumor explants show contributions of the tumor microenvironment to response of Dato-DXd ex vivo
Poster
I-DXd
AACR 2024 | April 5-10, 2024
In vivo efficacy of B7-H3 (CD276)-directed antibody-drug conjugate (ADC) ifinatamab deruxtecan (I-DXd; DS-7300a): An update from the pediatric preclinical in vivo testing (PIVOT) program
Poster
T-DXd
AACR 2024 | April 5-10, 2024
Leveraging advanced human lung models to explore mechanisms underlying T-DXd-associated interstitial lung disease (ILD)
Pages:
1 2